'My youngest son has ADOA, we found out about that about four years ago. His vision deteriorated from 80 to about 50 percent within a short period of time. Then we started looking and it turned out to be ADOA.' Through his son's diagnosis of ADOA, Ralph discovered that he himself is a carrier. 'My father, now deceased, also had very poor eyesight, so there is a good chance that he also had ADOA.'
Ralph's other children have been tested and do not have ADOA. 'We are happy that we know that now, but in retrospect we may have had them tested a little too quickly. Bartimeus advised us that and we did not really think about the possible consequences. When the clinical geneticist gave us the results, we only became aware that we could perhaps have waited until the children could decide for themselves whether they wanted to be tested.'
Ralph is involved with the Cure ADOA Foundation. He looks for ongoing investigations and tries to gather as much information as possible. 'How did you become involved with the foundation and what is your motivation for this work?'
'It started with the Facebook group, where I read an article about Stokes' research. I wrote to them and shared my results with the board. I came into contact with Hedy from the board and she had a large document with all kinds of research. I started looking into that. Lots of calling, emailing and asking questions. I make the first contacts with research organizations and try to separate the wheat from the chaff. Do we have to delve into something or is it still far too vague? I often do this together with a number of other board members of the foundation.'
Ralph is hopeful when it comes to investigations. ' Compared to 5 years ago, there is a lot of research in the field of ADOA, Glaucoma and Leber. There's a lot going on. There are two or three commercial companies seriously developing a drug for ADOA. I maintain close contacts with them. The researchers outline a timeframe of 5-10 years for treatment to keep vision stable. Unfortunately, it is a bit more difficult for ADOA+. Most researchers do not dare to say much about this yet. Other processes in the body also play a role. Gene therapy is also being worked on. That timeframe is closer to 10 years and there is also an expectation that there will be a limited degree of improvement in vision. So positive!'